

sub 1 cont'd

--19. A pharmaceutical composition containing
as active ingredient a compound according to claim 4.--;

1 --20. A method for inhibiting gastric acid
2 secretion by administering to mammals an amount of a
3 compound as defined in claim 1 sufficient to inhibit
4 gastric acid secretion.--;

1 --21. A method for inhibiting gastric acid
2 secretion by administering to mammals an amount of a
3 compound as defined in claim 2 sufficient to inhibit
4 gastric acid secretion.--;

1 --22. A method for inhibiting gastric acid
2 secretion by administering to mammals an amount of a
3 compound as defined in claim 3 sufficient to inhibit
4 gastric acid secretion.--;

1 --23. A method for inhibiting gastric acid
2 secretion by administering to mammals an amount of a
3 compound as defined in claim 4 sufficient to inhibit
4 gastric acid secretion.--;

1 --24. A method for the treatment of gastro-
2 intestinal inflammatory diseases in mammals by administer-
3 ing to mammals an amount of a compound as defined in
4 claim 1 sufficient to treat gastrointestinal inflammatory
5 disease.--;

1 --25. A method for the treatment of gastro-
2 intestinal inflammatory diseases in mammals by administer-
3 ing to mammals an amount of a compound as defined in
4 claim 2 sufficient to treat gastrointestinal inflammatory
5 disease.--;

BEST AVAILABLE COPY

A1
contd

BEST AVAILABLE COPY

13
1 --26. A method for the treatment of gastro-
2 intestinal inflammatory diseases in mammals by administer-
3 ing to mammals an amount of a compound as defined in
4 claim 3 sufficient to treat gastrointestinal inflammatory
5 disease.--;

14
1 --27. A method for the treatment of gastro-
2 intestinal inflammatory diseases in mammals by administer-
3 ing to mammals an amount of a compound as defined in
4 claim 4 sufficient to treat gastrointestinal inflammatory
5 disease.--;

15
1 --28. A method for providing gastrointestinal
2 cytoprotective effects in mammals by administering to
3 mammals an amount of a compound as defined in claim 1
4 sufficient to provide gastrointestinal cytoprotective
5 effects.--;

16
1 --29. A method for providing gastrointestinal
2 cytoprotective effects in mammals by administering to
3 mammals an amount of a compound as defined in claim 2
4 sufficient to provide gastrointestinal cytoprotective
5 effects.--;

17
1 --30. A method for providing gastrointestinal
2 cytoprotective effects in mammals by administering to
3 mammals an amount of a compound as defined in claim 3
4 sufficient to provide gastrointestinal cytoprotective
5 effects.--;

1 --31. A method for providing gastrointestinal
2 cytoprotective effects in mammals by administering to
3 mammals an amount of a compound as defined in claim 4
4 sufficient to provide gastrointestinal cytoprotective
5 effects. *[Signature]*

Respectfully submitted,

Mr. Andrew Lynn

Allan H. Bonnell
Patent Office Reg. No. 22,059

M. Andrea Ryan
Patent Office Req. No. 28,469

Attorneys for Applicant
(212) 408-2572

Enclosures

BEST AVAILABLE COPY